001     128951
005     20240228143359.0
024 7 _ |a 10.1080/15592294.2015.1137414
|2 doi
024 7 _ |a pmid:26786582
|2 pmid
024 7 _ |a pmc:PMC4846111
|2 pmc
024 7 _ |a 1559-2294
|2 ISSN
024 7 _ |a 1559-2308
|2 ISSN
024 7 _ |a altmetric:5022330
|2 altmetric
037 _ _ |a DKFZ-2017-04963
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Kostareli, Efterpi
|b 0
245 _ _ |a Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
260 _ _ |a Austin, Tex.
|c 2016
|b Landes Bioscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522135899_11164
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9%) and a low prevalence of HPV16-related tumors (8.8%) was analyzed by MassARRAY to determine a previously established prognostic methylation score (MS). Kaplan-Meier revealed a highly significant correlation between a high MS and a favorable survival for OPSCC (P = 0.0004) and for non-OPSCC (P<0.0001), which was confirmed for all HNSCC by multivariate Cox regression models (HR: 9.67, 95% CI [4.61-20.30], P<0.0001). Next, we established a minimal methylation signature score (MMSS), which consists of ten most informative of the originally 62 CpG units used for the MS. The prognostic value of the MMSS was confirmed by Kaplan-Meier analysis for all HNSCC (P<0.0001) and non-OPSCC (P = 0.0002), and was supported by multivariate Cox regression models for all HNSCC (HR: 2.15, 95% CI [1.36-3.41], P = 0.001). In summary, the MS and the MMSS exhibit an excellent performance as prognosticators for survival, which is not limited by the anatomical site, and both could be implemented in future clinical trials.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 1
|u dkfz
700 1 _ |a Zucknick, Manuela
|b 2
700 1 _ |a Baboci, Lorena
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Wichmann, Gunnar
|b 4
700 1 _ |a Holzinger, Dana
|0 P:(DE-He78)d84ca2cd7f160904c387ee699735076c
|b 5
|u dkfz
700 1 _ |a Mücke, Oliver
|b 6
700 1 _ |a Pawlita, Michael
|0 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
|b 7
|u dkfz
700 1 _ |a Del Mistro, Annarosa
|b 8
700 1 _ |a Boscolo-Rizzo, Paolo
|b 9
700 1 _ |a Da Mosto, Maria Cristina
|b 10
700 1 _ |a Tirelli, Giancarlo
|b 11
700 1 _ |a Plinkert, Peter
|b 12
700 1 _ |a Dietz, Andreas
|b 13
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 14
|u dkfz
700 1 _ |a Weichenhan, Dieter
|0 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
|b 15
|e Last author
|u dkfz
700 1 _ |a Hess, Jochen
|0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.1080/15592294.2015.1137414
|g Vol. 11, no. 1, p. 61 - 73
|0 PERI:(DE-600)2248598-3
|n 1
|p 61 - 73
|t Epigenetics
|v 11
|y 2016
|x 1559-2308
909 C O |o oai:inrepo02.dkfz.de:128951
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d84ca2cd7f160904c387ee699735076c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EPIGENETICS-US : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Molekulare Diagnostik Oncogener Infektionen
|x 0
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 1
920 1 _ |0 I:(DE-He78)G405-20160331
|k G405
|l Molekulare Grundlagen von HNO-Tumoren
|x 2
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a I:(DE-He78)G405-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21